Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0095121

—

2fccc86f-1d26-55dd-afc2-07b53b54cf68

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.400
  • INTERFERON_GAMMA_RESPONSE+0.400
  • E2F_TARGETS+0.300
  • INTERFERON_ALPHA_RESPONSE+0.300
  • MTORC1_SIGNALING+0.300
  • MYC_TARGETS_V2+0.300
  • SPERMATOGENESIS+0.300
  • UNFOLDED_PROTEIN_RESPONSE+0.300
  • DNA_REPAIR+0.200
  • G2M_CHECKPOINT+0.200

Top 10 suppressed

  • ANGIOGENESIS-0.600
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
  • NOTCH_SIGNALING-0.400
  • APICAL_JUNCTION-0.300
  • COAGULATION-0.300
  • ESTROGEN_RESPONSE_EARLY-0.300
  • HEDGEHOG_SIGNALING-0.300
  • TGF_BETA_SIGNALING-0.300
  • UV_RESPONSE_DN-0.300
  • WNT_BETA_CATENIN_SIGNALING-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-AR-A0TV-01A-21R-A084-07
breast-umap@18
—B0.873
2TCGA-C8-A1HM-01A-12R-A137-07
breast-umap@18
—C0.862
3SRR8518289
breast-umap@18
—E0.841
4s0112318
melanoma-umap@29
——0.840
5TCGA-18-3416-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.839
6C3N-04382
lung-landscapes@6
—cohortMD10.838
7SRR8518323
breast-umap@18
—E0.837
820080227.Her2HRpos
breast-umap@18
—C0.832
9SRR26320066
bladder-landscape@3
——0.828
10GSM6454730
breast-umap@18
—D0.828

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
MYC_TARGETS_V20.300Idelalisib— uncovered
SPERMATOGENESIS0.300Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
DNA_REPAIR0.200Idelalisib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
MYC_TARGETS_V10.200Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
PROTEIN_SECRETION0.200Remibrutinib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
MITOTIC_SPINDLE0.100Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
UV_RESPONSE_UP0.100Idelalisib— uncovered